Eterna Therapeutics Inc (ERNA) USD0.005

Sell:$0.35Buy:$0.37$0.00 (0.75%)

Prices delayed by at least 15 minutes
Sell:$0.35
Buy:$0.37
Change:$0.00 (0.75%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.35
Buy:$0.37
Change:$0.00 (0.75%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.

Key people

Sanjeev Luther
President, Chief Executive Officer, Director
Sandra Gurrola
Senior Vice President - Finance
Dorothy J. Clarke
General Counsel
James Bristol
Independent Chairman of the Board
Peter Cicala
Independent Director
Elena Ratner
Independent Director
William Wexler
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US1140822099
  • Market cap
    $19.44m
  • Employees
    8
  • Shares in issue
    51.37m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.